se ha leído el artículo
array:24 [ "pii" => "S1578219020300147" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.11.005" "estado" => "S300" "fechaPublicacion" => "2020-03-01" "aid" => "2275" "copyright" => "AEDV" "copyrightAnyo" => "2019" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2020;111:87" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0001731019303771" "issn" => "00017310" "doi" => "10.1016/j.ad.2019.11.001" "estado" => "S300" "fechaPublicacion" => "2020-03-01" "aid" => "2275" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2020;111:87" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 37 "formatos" => array:2 [ "HTML" => 19 "PDF" => 18 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Comentario editorial</span>" "titulo" => "Apremilast en psoriasis" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "87" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Apremilast in Psoriasis" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Pérez Ferriols" "autores" => array:1 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Pérez Ferriols" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219020300147" "doi" => "10.1016/j.adengl.2019.11.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219020300147?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731019303771?idApp=UINPBA000044" "url" => "/00017310/0000011100000002/v2_202009190635/S0001731019303771/v2_202009190635/es/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S1578219020300135" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.03.029" "estado" => "S300" "fechaPublicacion" => "2020-03-01" "aid" => "2193" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2020;111:87-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "Early Syphilis: New Diagnostic Approaches in a Changing Scenario" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "87" "paginaFinal" => "88" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Sífilis precoz: nuevas aproximaciones diagnósticas para un escenario cambiante" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "T. Toledo Pastrana" "autores" => array:1 [ 0 => array:2 [ "nombre" => "T." "apellidos" => "Toledo Pastrana" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731019301279" "doi" => "10.1016/j.ad.2019.03.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731019301279?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219020300135?idApp=UINPBA000044" "url" => "/15782190/0000011100000002/v1_202004140647/S1578219020300135/v1_202004140647/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "Apremilast in Psoriasis" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "87" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "A. Pérez Ferriols" "autores" => array:1 [ 0 => array:3 [ "nombre" => "A." "apellidos" => "Pérez Ferriols" "email" => array:1 [ 0 => "perez_ampferr@gva.es" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Dermatología, Hospital General Universitario, Valencia, Spain" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Apremilast en psoriasis" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">The authors present the results of a Delphi study conducted in Spain on the use of apremilast in psoriasis.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Apremilast is a “small-molecule” oral phosphodiesterase 4 inhibitor that according to its summary of product characteristics is indicated for the treatment of psoriatic arthritis and chronic moderate to severe plaque psoriasis. The position of apremilast in the current arsenal of treatments for psoriasis has been influenced by several factors. First, its limited effectiveness compared with other alternatives; second its adverse effects, which in many cases require withdrawal of treatment due to poor tolerability; and last but not least, its cost, which is similar to that of the most effective biologic drugs available and higher than that of other biosimilars.</p><p id="par0010" class="elsevierStylePara elsevierViewall">The authors, all experts in psoriasis, chose 5 points of interest to analyze using a Delphi questionnaire. After reviewing each point based on the existing literature, the panel concluded that apremilast might be a treatment option for patients with a different profile to that studied in the clinical trials. They highlight the need for a consensus-based definition of moderate psoriasis, which is where apremilast could possibly be positioned as a treatment option preceding biologic therapy. Finally, they stress the need for more scientific evidence from clinical trials and real-world studies to verify the opinions expressed in this study.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Pérez Ferriols A. Apremilast en psoriasis. Actas Dermosifiliogr. 2020;111:87.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Reference" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:1 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estudio Delphi para el uso de apremilast en psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.M. Carrascosa" 1 => "I. Belinchón" 2 => "R. Rivera" 3 => "M. Ara" 4 => "M. Bustinduy" 5 => "P. Herranz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Actas Dermosifilogr" "fecha" => "2020" "volumen" => "111" "paginaInicial" => "115" "paginaFinal" => "134" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000011100000002/v1_202004140647/S1578219020300147/v1_202004140647/en/main.assets" "Apartado" => array:4 [ "identificador" => "66476" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Commentaries" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011100000002/v1_202004140647/S1578219020300147/v1_202004140647/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219020300147?idApp=UINPBA000044" ]
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 8 | 11 | 19 |
2024 Octubre | 53 | 52 | 105 |
2024 Septiembre | 53 | 22 | 75 |
2024 Agosto | 82 | 57 | 139 |
2024 Julio | 49 | 34 | 83 |
2024 Junio | 56 | 21 | 77 |
2024 Mayo | 66 | 22 | 88 |
2024 Abril | 61 | 26 | 87 |
2024 Marzo | 57 | 28 | 85 |
2024 Febrero | 47 | 25 | 72 |
2024 Enero | 53 | 33 | 86 |
2023 Diciembre | 40 | 14 | 54 |
2023 Noviembre | 61 | 29 | 90 |
2023 Octubre | 45 | 12 | 57 |
2023 Septiembre | 34 | 35 | 69 |
2023 Agosto | 33 | 9 | 42 |
2023 Julio | 31 | 30 | 61 |
2023 Junio | 40 | 25 | 65 |
2023 Mayo | 35 | 20 | 55 |
2023 Abril | 25 | 20 | 45 |
2023 Marzo | 30 | 28 | 58 |
2023 Febrero | 38 | 22 | 60 |
2023 Enero | 22 | 25 | 47 |
2022 Diciembre | 37 | 41 | 78 |
2022 Noviembre | 20 | 29 | 49 |
2022 Octubre | 25 | 15 | 40 |
2022 Septiembre | 21 | 50 | 71 |
2022 Agosto | 26 | 32 | 58 |
2022 Julio | 28 | 38 | 66 |
2022 Junio | 19 | 29 | 48 |
2022 Mayo | 26 | 31 | 57 |
2022 Abril | 31 | 24 | 55 |
2022 Marzo | 27 | 40 | 67 |
2022 Febrero | 23 | 21 | 44 |
2022 Enero | 20 | 26 | 46 |
2021 Diciembre | 24 | 56 | 80 |
2021 Noviembre | 24 | 34 | 58 |
2021 Octubre | 43 | 52 | 95 |
2021 Septiembre | 18 | 36 | 54 |
2021 Agosto | 19 | 28 | 47 |
2021 Julio | 21 | 20 | 41 |
2021 Junio | 21 | 22 | 43 |
2021 Mayo | 37 | 44 | 81 |
2021 Abril | 71 | 44 | 115 |
2021 Marzo | 36 | 28 | 64 |
2021 Febrero | 31 | 21 | 52 |
2021 Enero | 29 | 16 | 45 |
2020 Diciembre | 27 | 19 | 46 |
2020 Noviembre | 19 | 10 | 29 |
2020 Octubre | 15 | 7 | 22 |
2020 Septiembre | 30 | 14 | 44 |
2020 Agosto | 28 | 14 | 42 |
2020 Julio | 11 | 7 | 18 |
2020 Junio | 18 | 22 | 40 |
2020 Mayo | 42 | 18 | 60 |
2020 Abril | 76 | 26 | 102 |
2020 Marzo | 10 | 12 | 22 |
2020 Febrero | 4 | 2 | 6 |